Showing results (211-220 of 221) with videos related to

Sort By:
Pageof 23
Cancers|October 14, 2022
The Impact of the Hippo Pathway and Cell Metabolism on Pathological Complete Response in Locally Advanced Her2+ Breast Cancer: The TRISKELE Multicenter Prospective StudyEriseld Krasniqi, Francesca Sofia Di Lisa, Anna Di Benedetto, et al.
United European Gastroenterology Journal|March 25, 2026
Efficacy and Safety of Second-Line Advanced Therapy After Vedolizumab in Ulcerative Colitis: A Multicenter Cohort Study From the GETAIDLouis Calméjane, Catherine Reenaers, Claire Gay, et al.
Biology Direct|June 23, 2025
Multimodal deep learning for predicting neoadjuvant treatment outcomes in breast cancer: a systematic reviewEriseld Krasniqi, Lorena Filomeno, Teresa Arcuri, et al.
NPJ Breast Cancer|May 29, 2026
Platinum-based neoadjuvant chemotherapy and the predictive role of DNA damage response biomarkers in TNBC: the NeoCarbo studyEriseld Krasniqi, Anna Di Benedetto, Lorena Filomeno, et al.
Updates in Surgery|February 14, 2014
The SIC-GIRCG 2013 Consensus Conference on Gastric CancerGiovanni De Manzoni, Gian Luca Baiocchi, Massimo Framarini, et al.
Additive Manufacturing|April 3, 2024
Results of an interlaboratory study on the working curve in vat photopolymerizationThomas J Kolibaba, Jason P Killgore, Benjamin W Caplins, et al.
Additive Manufacturing|May 4, 2026
Results of an Interlaboratory Study on the Working Curve in Vat Photopolymerization II: Towards a Standardized MethodThomas J Kolibaba, Jason P Killgore, Benjamin W Caplins, et al.
Cancers|December 17, 2024
Tolerability and Preliminary Outcomes of Adjuvant T-DM1 in HER2-Positive Breast Cancer After Neoadjuvant Therapy: The ATD StudyEriseld Krasniqi, Lorena Filomeno, Teresa Arcuri, et al.
Therapeutic Advances in Medical Oncology|February 17, 2022
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world settingLaura Pizzuti, Eriseld Krasniqi, Isabella Sperduti, et al.
Frontiers in Oncology|June 1, 2023
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from <i>CaRe</i>, a multicentric, observational studyFrancesca Sofia Di Lisa, Eriseld Krasniqi, Laura Pizzuti, et al.
Pageof 23